A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Clinical trial NCT06852963 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06852963
Sponsor: PYC Therapeutics
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Retinitis Pigmentosa 11 Retinal Degeneration Retinal Disease Eye Diseases Hereditary Retinal Dystrophies

Start date: 2025-06-01
Primary completion: 2028-03-08
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.